Dixon Hughes Goodman Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$0	Buy	+1	New	+$145	﹤0.01%	984

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's JAZZ Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2022: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #984 among its holdings.

461 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 1 share of Jazz Pharmaceuticals worth $0 as of Q1 2022.
Jazz Pharmaceuticals was a new Dixon Hughes Goodman Wealth Advisors position in Q1 2022.
Jazz Pharmaceuticals made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #984 holding.
461 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.